Literature DB >> 21130783

Circulating endothelial and endothelial progenitor cells in patients with severe sepsis.

Douglas E Schlichting1, Aaron B Waxman, Lee A O'Brien, Tiffany Wang, Chris C Naum, George J Rubeiz, Suzane L Um, Mark Williams, Sau-Chi Betty Yan.   

Abstract

Elevated circulating endothelial cell (CEC) and circulating endothelial progenitor cell (CEPC) counts may indicate vascular damage and disease status, but data on these cell populations in patients with severe sepsis are limited. This study compared CEC and CEPC counts in patients with and without severe sepsis following intensive care unit (ICU) admission. Venous blood samples were collected within 24 h, 48-72 h, and 120-144 h. Baseline demographics, 28-day mortality, ICU and hospital days, and Sequential Organ Failure Assessment (SOFA) scores were recorded. Patients with (n=18) and without (n=28) severe sepsis were balanced for mean age (63.7 and 61.3 years, respectively) and gender. There were no differences in 28-day mortality, ICU days, or hospital days. Baseline SOFA scores were higher in the sepsis group. At 48-72 h, patients with severe sepsis had significantly higher median CEC counts (51.5 vs. 28.0 cells/4 ml of blood, P=0.02). CEC values for all ICU patients were significantly (P<0.05) higher than in healthy volunteers. CEPC counts in both cohorts ranged from 0 to >21 colonies/4 ml blood (mean=1.13±2.25; median=0) without significant differences at any time point. This study demonstrates the ability to quantify CECs and CEPCs using consensus methodology. Understanding the relationship between CEC/CEPC counts and outcomes may provide insight into the mechanisms of endothelial cell changes in severe sepsis.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21130783     DOI: 10.1016/j.mvr.2010.11.011

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  8 in total

1.  Evaluation of endothelial damage in sepsis-related ARDS using circulating endothelial cells.

Authors:  Mouhamed Djahoum Moussa; Cristina Santonocito; David Fagnoul; Katia Donadello; Olivier Pradier; Pascale Gaussem; Daniel De Backer; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2014-12-16       Impact factor: 17.440

Review 2.  Endothelial Activation and Microcirculatory Disorders in Sepsis.

Authors:  Lisa Raia; Lara Zafrani
Journal:  Front Med (Lausanne)       Date:  2022-06-03

3.  Circulating hematopoietic and endothelial progenitor cells in newborn infants: effects of gestational age, postnatal age and clinical stress in the first 3 weeks of life.

Authors:  Kim Chi T Bui; Mark Weems; Manoj Biniwale; Aswathi A George; Ewa Zielinska; Colleen G Azen; Manuel Durand; Hisham Abdel-Azim
Journal:  Early Hum Dev       Date:  2013-01-09       Impact factor: 2.079

Review 4.  Metabolic theory of septic shock.

Authors:  Jay Pravda
Journal:  World J Crit Care Med       Date:  2014-05-04

Review 5.  Mobilization of endothelial progenitor cells in sepsis.

Authors:  Ran Sun; Jiamin Huang; Bingwei Sun
Journal:  Inflamm Res       Date:  2019-11-22       Impact factor: 4.575

6.  Lipopolysaccharide Induces Human Pulmonary Micro-Vascular Endothelial Apoptosis via the YAP Signaling Pathway.

Authors:  Lei Yi; Xiaoqin Huang; Feng Guo; Zengding Zhou; Mengling Chang; Jiajun Tang; Jingning Huan
Journal:  Front Cell Infect Microbiol       Date:  2016-10-19       Impact factor: 5.293

7.  CXCR-4 expression by circulating endothelial progenitor cells and SDF-1 serum levels are elevated in septic patients.

Authors:  Christian Patry; Daniela Stamm; Christian Betzen; Burkhard Tönshoff; Benito A Yard; Grietje Ch Beck; Neysan Rafat
Journal:  J Inflamm (Lond)       Date:  2018-05-16       Impact factor: 4.981

Review 8.  The endothelium, a protagonist in the pathophysiology of critical illness: focus on cellular markers.

Authors:  Sabrina H van Ierssel; Philippe G Jorens; Emeline M Van Craenenbroeck; Viviane M Conraads
Journal:  Biomed Res Int       Date:  2014-04-01       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.